Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on Capital EmployedReturn on Invested CapitalTimes Interest Earned

Lifecore Biomedical, Inc. \De\ (LFCR) Debt to Equity (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Debt to Equity over the past 15 years, most recently at $90.72 for Q2 2025.

  • Quarterly results put Debt to Equity at $90.72 for Q2 2025, up 910.38% from a year ago — trailing twelve months through May 2025 was $90.72 (up 910.38% YoY), and the annual figure for FY2025 was $90.72, up 910.38%.
  • Debt to Equity for Q2 2025 was $90.72 at Lifecore Biomedical, Inc. \De\, up from $51.89 in the prior quarter.
  • Over the last five years, Debt to Equity for LFCR hit a ceiling of $90.72 in Q2 2025 and a floor of -$6.55 in Q3 2023.
  • Median Debt to Equity over the past 5 years was $0.88 (2021), compared with a mean of $8.95.
  • Peak annual rise in Debt to Equity hit 1741.05% in 2023, while the deepest fall reached 1259.43% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Debt to Equity stood at $1.07 in 2021, then tumbled by 36.9% to $0.67 in 2022, then skyrocketed by 1741.05% to $12.42 in 2023, then tumbled by 95.17% to $0.6 in 2024, then surged by 15013.64% to $90.72 in 2025.
  • The last three reported values for Debt to Equity were $90.72 (Q2 2025), $51.89 (Q1 2025), and $0.6 (Q4 2024) per Business Quant data.